NIH State-of-the-Science Conference: Enhancing Use and Quality of Colorectal Cancer Screening, 2552-2553 [2010-666]
Download as PDF
<![CDATA[
jlentini on DSKJ8SOYB1PROD with NOTICES
2552
Federal Register / Vol. 75, No. 10 / Friday, January 15, 2010 / Notices
postmenopausal women. Very low
intake of vitamin D can lead to the
development of rickets, especially in
those of African descent and other
highly pigmented individuals. Although
milk alternative products are typically
fortified with vitamin D and other
nutrients, they are often more expensive
and less widely available than
conventional products.
The public health burden from
deficiencies attributable to lactose
intolerance is difficult to quantify.
Additionally, it is challenging to
identify and manage lactase
nonpersisters. Questions remain as to
the amount, if any, of lactose that can
be tolerated by lactose nonpersisters and
how best to assist these individuals in
meeting recommended intakes. To
examine these important issues, the
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development and the Office of Medical
Applications of Research of the National
Institutes of Health will convene a
Consensus Development Conference
from February 22 to 24, 2010, to assess
the available scientific evidence related
to the following questions:
• What is the prevalence of lactose
intolerance, and how does this
prevalence differ by race, ethnicity, and
age?
• What are the health outcomes of
dairy exclusion diets?
• What amount of daily lactose intake
is tolerable in subjects with diagnosed
lactose intolerance?
• What strategies are effective in
managing individuals with diagnosed
lactose intolerance?
• What are the future research needs
for understanding and managing lactose
intolerance?
An impartial, independent panel will
be charged with reviewing the available
published literature in advance of the
conference, including a systematic
literature review commissioned through
the Agency for Healthcare Research and
Quality. The first day and a half of the
conference will consist of presentations
by expert researchers and practitioners
and open public discussions. On
Wednesday, February 24, the panel will
present a statement of its collective
assessment of the evidence to answer
each of the questions above. The panel
will also hold a press telebriefing to
address questions from the media. The
draft statement will be published online
later that day, and the final version will
be released approximately six weeks
later. The primary sponsors of this
meeting are the NIH Eunice Kennedy
Shriver National Institute of Child
Health and Human Development and
VerDate Nov<24>2008
17:34 Jan 14, 2010
Jkt 220001
the NIH Office of Medical Applications
of Research.
Advance information about the
conference and conference registration
materials may be obtained from the NIH
Consensus Development Program
Information Center by calling 888–644–
2667 or by sending e-mail to
consensus@mail.nih.gov. The
Information Center’s mailing address is
P.O. Box 2577, Kensington, Maryland
20891. Registration information is also
available on the NIH Consensus
Development Program Web site at
https://consensus.nih.gov.
Please Note: The NIH has instituted
security measures to ensure the safety of NIH
employees, guests, and property. All visitors
must be prepared to show a photo ID upon
request. Visitors may be required to pass
through a metal detector and have bags,
backpacks, or purses inspected or x-rayed as
they enter NIH buildings. For more
information about the security measures at
NIH, please visit the Web site at https://
www.nih.gov/about/visitorsecurity.htm.
Dated: January 7, 2010.
Raynard S. Kington,
Deputy Director, National Institutes of Health.
[FR Doc. 2010–672 Filed 1–14–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
NIH State-of-the-Science Conference:
Enhancing Use and Quality of
Colorectal Cancer Screening
Notice is hereby given by the National
Institutes of Health (NIH) of the ‘‘NIH
State-of-the-Science Conference:
Enhancing Use and Quality of
Colorectal Cancer Screening’’ to be held
February 2–4, 2010, in the NIH Natcher
Conference Center, 45 Center Drive,
Bethesda, Maryland 20892. The
conference will begin at 8:30 a.m. on
February 2 and 3, and at 9 a.m. on
February 4, and will be open to the
public.
Colorectal cancer is the secondleading cause of cancer-related deaths in
the United States. Approximately
50,000 people in the United States are
expected to die from colorectal cancer
in 2009. Colonic polyps, abnormal
growths of tissue on the inner lining of
the colon, are relatively common
findings in men and women 50 years
and older. Most of these growths are not
cancerous, but one type of polyp,
known as an adenoma, can develop into
colorectal cancer. Screening tests for
colorectal cancer generally either seek to
identify and remove adenomas or
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
examine the stool for signs of early
cancer in people who have no
symptoms. A range of colorectal cancer
screening tests is available in the United
States. The U.S. Preventive Services
Task Force currently recommends that
average-risk adults aged 50 to 75 years
undergo screening for colorectal cancer
with annual fecal occult blood testing,
sigmoidoscopy (internal examination of
the lower part of the large intestine)
every 5 years, or colonoscopy (internal
examination of the entire large intestine)
every 10 years. Additional tests that
may be used for colorectal cancer
screening include computed
tomography (CT) colonography and
fecal DNA testing.
Although colorectal cancer is an
important cause of mortality in the
United States, screening for this disease
is currently underutilized among
eligible individuals. Despite evidence
supporting the value of screening, in
2005 only 50 percent of U.S. adults aged
50 and older had been screened
according to guidelines. Rates of
screening for colorectal cancer are
consistently lower than those for other
common cancers, particularly breast and
cervical cancer. Reasons for this
disparity are complex. Unlike most
other preventive services, in colorectal
cancer screening there are multiple test
options from which to choose, and
patients and providers may have
varying preferences for or access to the
tests. Successful completion of
colorectal cancer screening requires
effort on the part of the patient to obtain
stool samples for testing or to clean the
colon in preparation for endoscopic
examination. Test options may also
differ in cost and availability for a given
community. Patient, provider, and
healthcare system characteristics may
each play a unique role in influencing
the use and quality of colorectal cancer
screening.
Adding to the complexity of this
issue, colorectal cancer screening may
be overused or misused in certain
situations. Despite uncertainty regarding
the benefit of removing small polyps,
many people undergoing sigmoidoscopy
or colonoscopy have all identified
growths removed. This may put them at
increased risk for possible
complications from these procedures,
which can include rectal bleeding or
colonic perforation (a tear in the wall of
the intestine that can cause a serious
abdominal infection). In addition,
follow-up testing of individuals who
have previously had polyps removed
may occur more frequently than
available evidence supports, which
again may put people at risk for
complications and have both cost and
E:\FR\FM\15JAN1.SGM
15JAN1
jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 10 / Friday, January 15, 2010 / Notices
capacity implications for the healthcare
system.
To provide healthcare providers,
patients, policy makers, and the general
public with a comprehensive
assessment of how colorectal cancer
screening and surveillance are most
appropriately implemented, monitored,
and evaluated for average-risk
populations in the United States, the
National Cancer Institute and the Office
of Medical Applications of Research of
the National Institutes of Health will
convene a State-of-the-Science
Conference February 2–4, 2010, to
assess the available scientific evidence
related to the following questions:
• What are the recent trends in the
use and quality of colorectal cancer
screening?
• What factors influence the use of
colorectal cancer screening?
• Which strategies are effective in
increasing the appropriate use of
colorectal cancer screening and followup?
• What are the current and projected
capacities to deliver colorectal cancer
screening and surveillance at the
population level?
• What are the effective approaches
for monitoring the use and quality of
colorectal cancer screening?
• What research is needed to make
the most progress and have the greatest
public health impact in promoting the
appropriate use of colorectal cancer
screening?
An impartial, independent panel will
be charged with reviewing the available
published literature in advance of the
conference, including a systematic
literature review commissioned through
the Agency for Healthcare Research and
Quality. The first day and a half of the
conference will consist of presentations
by expert researchers and practitioners
and open public discussions. On
Thursday, February 4, the panel will
present a statement of its collective
assessment of the evidence to answer
each of the questions above. The panel
will also hold a press telebriefing to
address questions from the media. The
draft statement will be published online
later that day, and the final version will
be released approximately six weeks
later. The primary sponsors of this
meeting are the NIH National Cancer
Institute and the NIH Office of Medical
Applications of Research.
Advance information about the
conference and conference registration
materials may be obtained from the NIH
Consensus Development Program
Information Center by calling 888–644–
2667 or by sending e-mail to
consensus@mail.nih.gov. The
Information Center’s mailing address is
VerDate Nov<24>2008
17:34 Jan 14, 2010
Jkt 220001
P.O. Box 2577, Kensington, Maryland
20891. Registration information is also
available on the NIH Consensus
Development Program Web site at
https://consensus.nih.gov.
Please Note: The NIH has instituted
security measures to ensure the safety of
employees, guests, and property. All visitors
must be prepared to show a photo ID upon
request. Visitors may be required to pass
through a metal detector and have bags,
backpacks, or purses inspected or x-rayed as
they enter NIH buildings. For more
information about the security measures at
NIH, please visit the Web site at https://
www.nih.gov/about/visitorsecurity.htm.
Dated: January 6, 2010.
Raynard S. Kington,
Deputy Director, National Institutes of Health.
[FR Doc. 2010–666 Filed 1–14–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Moving Into the Future—New
Dimensions and Strategies for
Women’s Health Research for the
National Institutes of Health; Notice
Notice is hereby given that the Office
of Research on Women’s Health
(ORWH), Office of the Director, National
Institutes of Health, Department of
Health and Human Services, in
collaboration with the Emory University
School of Medicine will convene a
public hearing and scientific workshop
February 16–17, 2010, at Emory
University School of Medicine, James B.
Williams Medical Education Building,
Atlanta, Georgia.
Purpose of the Meeting
With rapid advances in science and
wider global understanding of women’s
health and sex/gender contributions to
well-being and disease, the purpose of
the meeting is to ensure that NIH
continues to support cutting edge
women’s health research that is based
upon the most advanced techniques and
methodologies. The meeting format is
designed to promote an interactive
discussion involving leading scientists,
advocacy groups, public policy experts,
health care providers, and the general
public. With a focus upon women’s
cardiovascular health, the meeting at
Emory University School of Medicine is
convened to assist the ORWH and the
NIH to move into the next decade of
women’s health research.
As science and technology advance
and fields such as computational
biology demonstrate the power of
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
2553
interdisciplinary research, it remains
critical for sex and gender factors to be
integrated into broad experimental
methodologies and scientific
approaches across the lifespan.
Biomedical and behavioral research are
also necessary to understand how
cultural, ethnic, and racial differences
influence the causes, diagnosis,
progression, treatment, and outcome of
disease among different populations,
including women of diverse geographic
locations and socioeconomic
backgrounds. Furthermore, health
differences among diverse populations
of women remain a critical area in need
of continued focus and attention.
The ORWH challenges all meeting
attendees to assist the NIH in defining
the women’s health research agenda of
the future by thinking beyond
traditional women’s health issues. With
a special focus upon women’s
cardiovascular health, ORWH and NIH
ask meeting participants to consider
creative strategies that need to be
employed to identify areas of research
that are best poised for advancement,
identify innovative ways in which
persistent issues of health and disease
can be addressed, and explore new
horizons of scientific concepts and
investigative approaches. Attention also
needs to be paid to new areas of science
application, new technologies, and
continuing basic science investigations.
Clinical questions that are not currently
the focus of research priorities need to
be considered to ensure that women’s
health research is optimally served and
that the ORWH can continue to provide
leadership for the benefit of women’s
health, nationally and internationally.
Meeting Format
The meeting will consist of public
testimony, scientific panels and seven
concurrent scientific working groups.
Specifically, on February 16,
individuals representing a full spectrum
of organizations interested in
biomedical and behavioral research on
women’s health issues will have an
opportunity to provide public testimony
from 10:30 a.m.–12 p.m. The seven
concurrent scientific working groups
meeting on February 16 in afternoon
sessions will focus on a range of
women’s cardiovascular health issues,
including the following: pregnancy and
cardiovascular disease research and
ethical considerations; cardiovascular
disease in elderly and frail elderly
women—optimal management and
research; microvascular disease,
biomechanics, and application of new
technologies to cardiovascular research;
stem cells, progenitor cells, and the
vista of cardiovascular regenerative
E:\FR\FM\15JAN1.SGM
15JAN1
]]>Agencies
[Federal Register Volume 75, Number 10 (Friday, January 15, 2010)]
[Notices]
[Pages 2552-2553]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-666]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
NIH State-of-the-Science Conference: Enhancing Use and Quality of
Colorectal Cancer Screening
Notice is hereby given by the National Institutes of Health (NIH)
of the ``NIH State-of-the-Science Conference: Enhancing Use and Quality
of Colorectal Cancer Screening'' to be held February 2-4, 2010, in the
NIH Natcher Conference Center, 45 Center Drive, Bethesda, Maryland
20892. The conference will begin at 8:30 a.m. on February 2 and 3, and
at 9 a.m. on February 4, and will be open to the public.
Colorectal cancer is the second-leading cause of cancer-related
deaths in the United States. Approximately 50,000 people in the United
States are expected to die from colorectal cancer in 2009. Colonic
polyps, abnormal growths of tissue on the inner lining of the colon,
are relatively common findings in men and women 50 years and older.
Most of these growths are not cancerous, but one type of polyp, known
as an adenoma, can develop into colorectal cancer. Screening tests for
colorectal cancer generally either seek to identify and remove adenomas
or examine the stool for signs of early cancer in people who have no
symptoms. A range of colorectal cancer screening tests is available in
the United States. The U.S. Preventive Services Task Force currently
recommends that average-risk adults aged 50 to 75 years undergo
screening for colorectal cancer with annual fecal occult blood testing,
sigmoidoscopy (internal examination of the lower part of the large
intestine) every 5 years, or colonoscopy (internal examination of the
entire large intestine) every 10 years. Additional tests that may be
used for colorectal cancer screening include computed tomography (CT)
colonography and fecal DNA testing.
Although colorectal cancer is an important cause of mortality in
the United States, screening for this disease is currently
underutilized among eligible individuals. Despite evidence supporting
the value of screening, in 2005 only 50 percent of U.S. adults aged 50
and older had been screened according to guidelines. Rates of screening
for colorectal cancer are consistently lower than those for other
common cancers, particularly breast and cervical cancer. Reasons for
this disparity are complex. Unlike most other preventive services, in
colorectal cancer screening there are multiple test options from which
to choose, and patients and providers may have varying preferences for
or access to the tests. Successful completion of colorectal cancer
screening requires effort on the part of the patient to obtain stool
samples for testing or to clean the colon in preparation for endoscopic
examination. Test options may also differ in cost and availability for
a given community. Patient, provider, and healthcare system
characteristics may each play a unique role in influencing the use and
quality of colorectal cancer screening.
Adding to the complexity of this issue, colorectal cancer screening
may be overused or misused in certain situations. Despite uncertainty
regarding the benefit of removing small polyps, many people undergoing
sigmoidoscopy or colonoscopy have all identified growths removed. This
may put them at increased risk for possible complications from these
procedures, which can include rectal bleeding or colonic perforation (a
tear in the wall of the intestine that can cause a serious abdominal
infection). In addition, follow-up testing of individuals who have
previously had polyps removed may occur more frequently than available
evidence supports, which again may put people at risk for complications
and have both cost and
[[Page 2553]]
capacity implications for the healthcare system.
To provide healthcare providers, patients, policy makers, and the
general public with a comprehensive assessment of how colorectal cancer
screening and surveillance are most appropriately implemented,
monitored, and evaluated for average-risk populations in the United
States, the National Cancer Institute and the Office of Medical
Applications of Research of the National Institutes of Health will
convene a State-of-the-Science Conference February 2-4, 2010, to assess
the available scientific evidence related to the following questions:
What are the recent trends in the use and quality of
colorectal cancer screening?
What factors influence the use of colorectal cancer
screening?
Which strategies are effective in increasing the
appropriate use of colorectal cancer screening and follow-up?
What are the current and projected capacities to deliver
colorectal cancer screening and surveillance at the population level?
What are the effective approaches for monitoring the use
and quality of colorectal cancer screening?
What research is needed to make the most progress and have
the greatest public health impact in promoting the appropriate use of
colorectal cancer screening?
An impartial, independent panel will be charged with reviewing the
available published literature in advance of the conference, including
a systematic literature review commissioned through the Agency for
Healthcare Research and Quality. The first day and a half of the
conference will consist of presentations by expert researchers and
practitioners and open public discussions. On Thursday, February 4, the
panel will present a statement of its collective assessment of the
evidence to answer each of the questions above. The panel will also
hold a press telebriefing to address questions from the media. The
draft statement will be published online later that day, and the final
version will be released approximately six weeks later. The primary
sponsors of this meeting are the NIH National Cancer Institute and the
NIH Office of Medical Applications of Research.
Advance information about the conference and conference
registration materials may be obtained from the NIH Consensus
Development Program Information Center by calling 888-644-2667 or by
sending e-mail to consensus@mail.nih.gov. The Information Center's
mailing address is P.O. Box 2577, Kensington, Maryland 20891.
Registration information is also available on the NIH Consensus
Development Program Web site at https://consensus.nih.gov.
Please Note: The NIH has instituted security measures to ensure
the safety of employees, guests, and property. All visitors must be
prepared to show a photo ID upon request. Visitors may be required
to pass through a metal detector and have bags, backpacks, or purses
inspected or x-rayed as they enter NIH buildings. For more
information about the security measures at NIH, please visit the Web
site at https://www.nih.gov/about/visitorsecurity.htm.
Dated: January 6, 2010.
Raynard S. Kington,
Deputy Director, National Institutes of Health.
[FR Doc. 2010-666 Filed 1-14-10; 8:45 am]
BILLING CODE 4140-01-P
